Summary

Market Size & Trends

The Middle East & Africa blood-based biomarker for Alzheimer’s disease diagnostics market size was estimated at USD 6.22 million in 2024 and is expected to reach USD 13.11 million by 2033, growing at a CAGR of 9.77% from 2025 to 2033. Rising awareness of neurodegenerative diseases, coupled with an aging population across the region, is fueling demand for early detection tools. Traditionally, Alzheimer’s diagnosis has relied on expensive and invasive methods such as PET imaging or cerebrospinal fluid (CSF) testing, which are often limited in availability across MEA. Blood-based biomarkers offer a cost-effective, scalable, and minimally invasive alternative, making them particularly attractive in regions with constrained healthcare infrastructure.

As governments prioritize healthcare modernization and invest in early detection programs, adoption of blood biomarker tests is expected to expand. Market growth is also supported by international collaborations, local clinical trials, and the entry of global biotech companies into MEA, further bridging the gap between advanced Western technologies and regional healthcare needs.

Population aging and the regional dementia burden are powerful demand drivers. The Arab world had ~1.33 million people with dementia in 2021, while the WHO estimates 57 million globally (60-70% Alzheimer’s), with most cases in low/middle-income countries-categories that include many MEA markets. In Africa, studies report dementia incidence ~13.3 per 1,000 person-years and wide prevalence ranges (2.3–20%), underscoring unmet diagnostic need. Five reasons this pushes BBMs: (1) growing at-risk 65+ cohorts; (2) earlier detection improves care planning; (3) primary-care-friendly testing expands reach; (4) caregiver and societal burden pressures ministries to act; and (5) health-system KPI shifts toward chronic-disease management. Country snapshots illustrate heterogeneity: Lebanon shows high point prevalence (~828/100k), while the UAE is lower (~652/100k)-but rapid population aging and high health spending can still sustain demand. Together, these epidemiological realities create a durable, multi-year addressable market for AD BBMs.

Capital flows into MEA healthcare expand diagnostic capacity and BBM adoption. Saudi Arabia’s Vision 2030 Health Sector Transformation Program is overhauling delivery models, while 2024 budget updates cite USD 57 billion for health/social development-funds that often translate into new labs, LIMS, and quality programs.

MEA Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East & Africa blood-based biomarker for Alzheimer’s disease diagnostics market report based on type, technology, end-use, and country:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Amyloid-related markers
• Tau-related markers
• Neurodegeneration
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoassays
• Mass spectrometry-based assays
• Next-generation platforms
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical laboratories & hospital labs
• Pharma & biotech
• Academic & research institutes
• Others
• Country Outlook (Revenue, USD Million, 2021 - 2033)
• South Africa
• Saudi Arabia
• UAE
• Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Type Segment
1.1.1.2. Technology Segment
1.1.1.3. End Use Segment
1.2. Estimates and Forecast Timeline
1.3. Objectives
1.3.1. Objective - 1
1.3.2. Objective - 2
1.3.3. Objective - 3
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information or Data Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Validation
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. List of Abbreviations
Chapter 2. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Executive Summary
2.1. Market Snapshot
2.2. Type and Technology Snapshot
2.3. End Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Regulatory approvals and clinical validation
3.4.2. Rising demand for early and non-invasive diagnosis
3.4.3. Integration with disease-modifying therapies (DMTS)
3.5. Market Restraint Analysis
3.5.1. Reimbursement and coverage challenges
3.5.2. Standardization and validation barriers
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis
Chapter 4. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Type Estimates & Trend Analysis
4.1. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Type Movement Analysis
4.2. Amyloid-related markers
4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Tau-related markers
4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Neurodegeneration
4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Others
4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Technology Estimates & Trend Analysis
5.1. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Technology Movement Analysis
5.2. Immunoassays
5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Mass spectrometry-based assays
5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Next-generation platforms
5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Others
5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: End Use Estimates & Trend Analysis
6.1. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: End Use Movement Analysis
6.2. Clinical laboratories & hospital labs
6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. Pharma & biotech
6.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Academic & research institutes
6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Others
6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Regional Business Analysis
7.1. Regional Market Snapshot
7.2. Middle East and Africa
7.2.1. Middle East and Africa Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
7.2.2. South Africa
7.2.2.1. South Africa Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021 - 2033 (USD Million)
7.2.2.2. Key Country Dynamics
7.2.2.3. Regulatory Framework
7.2.2.4. Reimbursement Scenario
7.2.2.5. Competitive Scenario
7.2.3. Saudi Arabia
7.2.3.1. Saudi Arabia Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021 - 2033 (USD Million)
7.2.3.2. Key Country Dynamics
7.2.3.3. Regulatory Framework
7.2.3.4. Reimbursement Scenario
7.2.3.5. Competitive Scenario
7.2.4. UAE
7.2.4.1. UAE Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021 - 2033 (USD Million)
7.2.4.2. Key Country Dynamics
7.2.4.3. Regulatory Framework
7.2.4.4. Reimbursement Scenario
7.2.4.5. Competitive Scenario
7.2.5. Kuwait
7.2.5.1. Kuwait Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market, 2021 - 2033 (USD Million)
7.2.5.2. Key Country Dynamics
7.2.5.3. Regulatory Framework
7.2.5.4. Reimbursement Scenario
7.2.5.5. Competitive Scenario
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. NEW PRODUCT LAUNCH
8.2.2. PARTNERSHIPS
8.2.3. ACQUISITION
8.2.4. COLLABORATION
8.2.5. FUNDING
8.3. Key Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Company Profiles
8.5.1. F. Hoffmann-La Roche Ltd
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Quanterix
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Fujirebio
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. C2N Diagnostics
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Quest Diagnostics Incorporated
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. ALZpath
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Bio-Techne
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Alamar Biosciences, Inc.
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Beckman Coulter
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives